CTRI/2010/091/001280已完成4 期
A multicentre, open label, observational, non-interventional study to evaluate the safety and effectiveness of liraglutide in subjects with type 2 diabetes mellitus in India
ovo Nordisk India Private Ltd0 个研究点目标入组 1,386 人开始时间: 待定最近更新:
试验速览
- 阶段
- 4 期
- 状态
- 已完成
- 发起方
- 入组人数
- 1,386
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Pms
入排标准
入选标准
- •Subjects with Type 2 Diabetes, including newly-diagnosed patients / those already receiving other anti-diabetic medications including GLP-1 analogues, who require treatment with liraglutide according to the clinical judgment of their treating physician
- •Subjects who are capable of giving study-specific signed informed consent before any collection of information
- •Age 18 years and older
排除标准
- •Subjects with type 1 diabetes
- •Subjects who are or have previously been on liraglutide
- •Subjects who have previously been enrolled in the study
- •Subjects who are participating in another clinical trial
- •Subjects with a hypersensitivity to liraglutide or to any of the excipients (Disodium phosphate dihydrate, propylene glycol, phenol, water for injections)
- •Subjects who are pregnant, breast feeding or have the intention of becoming pregnant within the following 6 months
研究者
相似试验
已完成
不适用
Observational study comparing the safety and tolerability of Somatuline (Registered trade mark) Autogel (Registered trade mark) injected by Health Care Professionals and patients who inject at home for the treatment of acromegaly.Metabolic and Endocrine - Other metabolic disordersAcromegalyACTRN12608000606381Ipsen Pty Ltd38
已完成
不适用
Observational study comparing the safety and tolerability of Somatuline (Registered trade mark) Autogel (Registered trade mark) injected by Health Care Professionals and patients who inject at home for the treatment of neuroendocrine tumours.euroendocrine TumoursNeuroendocrine TumoursCancer - Neuroendocrine tumour (NET)ACTRN12609000226202Ipsen Pty Ltd25
进行中（未招募）
1 期
Abiraterone treatment for patients with relapsed ovarian cancer.EUCTR2013-000293-29-GBThe Royal Marsden NHS Foundation Trust47
已完成
不适用
A prospective, open label, multi-centre, observational, post-market study evaluating Juvéderm® Volift with Lidocaine for the correction of moderate to severe nasolabial folds (NLF)gezichtverouderingdermal fillersfacial agingNL-OMON37130Allergan Pharmaceuticals Ireland23
招募中
4 期
A post marketing surveillance study to evaluate safety and efficacy of fixed dose combination of Ceftriaxone + Sulbactam (Sulbactomax) in patients with various bacterial infectionsCTRI/2012/04/002558Venus Remedies Limited2,500